Skip to main content
Conference Coverage

Trastuzumab, Pertuzumab, and Docetaxel Remains Standard of Care for Older Patients With HER2-Positive Metastatic Breast Cancer

Featuring Akihiko Shimomura, MD

 

Akihiko Shimomura, MD, PhD, National Center for Global Health and Medicine, Tokyo, Japan, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic breast cancer.

These results were first presented at the 2023 San Antonio Breast Cancer Symposium.


Source:

Shimomura A, Tamura K, Sasaki K, et al. A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer. (JCOG1607 HERB TEA study). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract RF02-04

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.